Postmenopause
Perimenopause
Menopause
Hot Flashes
Premenopause
Estrogen Replacement Therapy
Follicle Stimulating Hormone
Longitudinal Studies
Aging
Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants. (1/3881)
Glutathione-S-transferases catalyze the detoxication of carcinogen metabolites and reactive oxygen species (ROS) produced through a number of mechanisms. Glutathione-S-transferase (GST) M1 is polymorphic, and the null allele results in a lack of enzyme activity. Because there are indications that ROS may be involved in breast carcinogenesis, we sought to determine whether the GSTM1 null allele was associated with increased breast cancer, particularly among women with lower consumption of dietary sources of alpha-tocopherol, carotenoids and ascorbic acid. In a study of diet and cancer in western New York, women with primary, incident, histologically confirmed breast cancer (n = 740) and community controls (n = 810) were interviewed and an extensive food-frequency questionnaire administered. A subset of these women provided a blood specimen. DNA was extracted and genotyping performed for GSTM1. Data were available for 279 cases and 340 controls. The null allele did not increase breast cancer risk, regardless of menopausal status. There were also no differences in associations between the polymorphism and risk among lower and higher consumers of dietary sources of antioxidants or smokers and nonsmokers. These results indicate that GSTM1 genetic polymorphisms are not associated with breast cancer risk, even in an environment low in antioxidant defenses. (+info)Tumour necrosis factor-alpha (TNF-alpha) in human endometrium and uterine secretion: an evaluation by immunohistochemistry, ELISA and semiquantitative RT-PCR. (2/3881)
Tumour necrosis factor-alpha (TNF-alpha is a pleiotropic cytokine synthesized throughout the female reproductive tract. Even though evidence has accumulated that supports its role in autocrine and paracrine processes, its expression and function in the human endometrium are still not completely understood. To gain a better understanding of the synthesis and release of TNF-alpha in the endometrium and how this relates to concentrations in uterine secretion, its expression throughout the menstrual cycle was investigated by three different techniques. Samples of endometrial tissue and uterine secretions were collected from patients undergoing abdominal and vaginal hysterectomy for benign reasons. The mRNA expression of TNF-alpha was investigated in homogenized endometrial tissue by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) (n = 18). An assessment of the cellular TNF-alpha protein localization in the endometrial glands was performed immunohistochemically (n = 39). The concentrations of the secreted TNF-alpha protein in endometrial secretion were determined by enzyme-linked immunosorbent analysis (n = 30). All three methods gave similar results on the temporal expression of TNF-alpha mRNA and TNF-alpha protein during the cycle. Concentrations of endometrial TNF-alpha mRNA in tissue samples and TNF-alpha protein in uterine secretion were quite low at the beginning of the cycle, rose sharply in the mid- to late proliferative phase and decreased towards the end of the cycle. The concentrations of TNF-alpha protein in the endometrial glands, as shown by immunohistochemical investigation, stayed high throughout the secretory phase at values slightly below those of the late proliferative phase. (+info)Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. (3/3881)
OBJECTIVE: To study the effect of cyclic etidronate in secondary prevention of corticosteroid induced osteoporosis. METHODS: A double blind, randomised placebo controlled study comparing cyclic etidronate and placebo during two years in 37 postmenopausal women receiving long term corticosteroid treatment, mainly for polymyalgia rheumatica (40% of the patients) and rheumatoid arthritis (30%). Bone density was measured in the lumbar spine, femoral neck, and femoral trochanter. RESULTS: After two years of treatment there was a significant difference between the groups in mean per cent change from baseline in bone density in the spine in favour of etidronate (p = 0.003). The estimated treatment difference (mean (SD)) was 9.3 (2.1)%. Etidronate increased bone density in the spine (4.9 (2.1)%, p < 0.05) whereas the placebo group lost bone (-2.4 (1.6)%). At the femoral neck there was an estimated difference of 5.3 (2.6)% between the groups (etidronate: 3.6% (1.4)%, p < 0.05, placebo: -2.4 (2.1)%). The estimated difference at the trochanter was 8.2 (3.0) (etidronate: 9.0 (1.5)%, p < 0.0001, placebo: 0.5 (2.3)%). No significant bone loss occurred in the hip in placebo treated patients. CONCLUSIONS: Cyclic etidronate is an effective treatment for postmenopausal women receiving corticosteroid treatment and is well tolerated. (+info)Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. (4/3881)
Prostate-specific antigen (PSA) is a serine protease which may play a role in a variety of cancer types, including breast cancer. In the present study, we evaluated whether the level of PSA in breast tumour cytosol could be associated with prognosis in primary breast cancer, or with response to tamoxifen therapy in recurrent disease. PSA levels were determined by enzyme-linked immunosorbent assay (ELISA) in breast tumour cytosols, and were correlated with prognosis in 1516 patients with primary breast cancer and with response to first-line tamoxifen therapy in 434 patients with recurrent disease. Relating the levels of PSA with classical prognostic factors, low levels were more often found in larger tumours, tumours of older and post-menopausal patients, and in steroid hormone receptor-negative tumours. There was no significant association between the levels of PSA with grade of differentiation or the number of involved lymph nodes. In patients with primary breast cancer, PSA was not significantly related to the rate of relapse, and a positive association of PSA with an improved survival could be attributed to its relationship to age. In patients with recurrent breast cancer, a high level of PSA was significantly related to a poor response to tamoxifen therapy, and a short progression-free and overall survival after start of treatment for recurrent disease. In Cox multivariate analyses for response to therapy and for (progression-free) survival, corrected for age/menopausal status, disease-free interval, site of relapse and steroid hormone receptor status, PSA was an independent variable of poor prognosis. It is concluded that the level of PSA in cytosols of primary breast tumours might be a marker to select breast cancer patients who may benefit from systemic tamoxifen therapy. (+info)Menopausal status and distensibility of the common carotid artery. (5/3881)
Although several studies have shown that exogenous estrogens have beneficial effects on arterial characteristics, the effect of endogenous estrogen on the vascular system is still unknown. In this study, distensibility, an indicator of arterial elasticity, of the common carotid artery was compared in pre- and postmenopausal women. The study comprised 93 premenopausal and 93 postmenopausal women of similar age (range, 43 to 55 years). Women were selected from respondents to a mailed questionnaire about the menopause, which was sent to all women aged 40 to 60 years in the Dutch town of Zoetermeer (n=12 675). Postmenopausal women who were at least 3 years past natural menopause or whose menses had stopped naturally before age 48, were age-matched with premenopausal women with regular menses and without menopausal complaints. The selection aimed at maximizing the contrast in estrogen status between pre- and postmenopausal women of the same age. Distensibility of the carotid artery was measured noninvasively with B-mode ultrasound and a vessel wall movement detector system. Arterial distensibility is expressed as the change in arterial diameter (distension, DeltaD) with the cardiac cycle, adjusted for lumen diameter, pulse pressure, and mean arterial blood pressure. Compared with premenopausal women, postmenopausal women had significantly lower arterial distension (DeltaD 370.5 microm [SE 9.5] versus 397.3 microm [SE 9.6]). These results suggest that the distensibility of the common carotid artery is negatively affected by natural menopause in presumed healthy women. (+info)Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. (6/3881)
BACKGROUND: Currently there is considerable interest in the potential health benefits of oil seeds, such as soy and flaxseed, especially in relation to cardiovascular disease and cancer. OBJECTIVE: We therefore evaluated health aspects of partially defatted flaxseed in relation to serum lipids, indicators of oxidative stress, and ex vivo sex hormone activities. DESIGN: Twenty-nine hyperlipidemic subjects (22 men and 7 postmenopausal women) completed two 3-wk treatment periods in a randomized, crossover trial. Subjects were given muffins that contributed approximately 20 g fiber/d from either flaxseed (approximately 50 g partially defatted flaxseed/d) or wheat bran (control) while they consumed self-selected National Cholesterol Education Program Step II diets. Both muffins had similar macronutrient profiles. Treatment phases were separated by > or = 2 wk. RESULTS: Partially defatted flaxseed reduced total cholesterol (4.6+/-1.2%; P = 0.001), LDL cholesterol (7.6+/-1.8%; P < 0.001), apolipoprotein B (5.4+/-1.4%; P = 0.001), and apolipoprotein A-I (5.8+/-1.9%; P = 0.005), but had no effect on serum lipoprotein ratios at week 3 compared with the control. There were no significant effects on serum HDL cholesterol, serum protein carbonyl content, or ex vivo androgen or progestin activity after either treatment. Unexpectedly, serum protein thiol groups were significantly lower (10.8+/-3.6%; P = 0.007) at week 3 after the flaxseed treatment than after the control, suggesting increased oxidation. CONCLUSIONS: These data indicate that partially defatted flaxseed is effective in lowering LDL cholesterol. No effects on lipoprotein ratios, ex vivo serum androgen or progestin activity, or protein carbonyl content were observed. The significance of increased oxidation of protein thiol groups with flaxseed consumption requires further investigation. (+info)Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women. (7/3881)
A randomized open trial of hormone replacement therapy was used to assess changes in adductor pollicis muscle strength during 6-12 months of treatment with Prempak C 0.625(R) in comparison with an untreated control group. Muscle strength (maximal voluntary force; MVF), muscle cross-sectional area and bone mineral density were measured. Women entering the trial had oestrogen levels below 150 pmol.l-1, confirming their post-menopausal hormonal status. In the treated group, MVF increased by 12.4+/-1.0% (mean+/-S.E.M.) of initial MVF over the duration of treatment, while it declined slightly (2.9+/-0.9%) in the control group. This increase in strength could not be explained by an increase in muscle bulk, there being no significant increase in cross-sectional area during the study. Those subjects who were weakest at enrolment showed the greatest increases in muscle strength after treatment. Bone mineral density in total hip, Ward's triangle and total spine increased in the treated group, in agreement with previous studies. There was no correlation between the individual increases in bone mineral density and those in MVF. (+info)Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. (8/3881)
BACKGROUND: There is compelling evidence that estrogens influence breast cancer risk. Since the mid-1980s, dietary fat intervention studies have been conducted to investigate the effect of fat intake on endogenous estrogen levels. To further our understanding of the possible relationship between dietary fat and breast cancer, we conducted a meta-analysis of dietary fat intervention studies that investigated serum estradiol levels, and we reviewed the nature of the evidence provided by prospective analytic studies of fat consumption and breast cancer risk. METHODS: A computerized search of the English language literature on estrogen/estradiol and dietary fat intervention studies published from January 1966 through June 1998 was conducted using the MEDLINE database. Pooled estimates were derived from the change in estradiol levels associated with fat reduction from 13 studies. Analyses were conducted separately for premenopausal and postmenopausal women and in both groups combined. RESULTS AND CONCLUSIONS: Statistically significant reductions in serum estradiol levels of -7.4% (95% confidence interval [CI] = -11.7% to -2.9%) among premenopausal women and -23.0% (95% CI = -27.7% to -18.1%) among postmenopausal women were observed, with an overall -13.4% (95% CI = -16.6% to -10.1%) reduction observed. The greatest reductions occurred in two studies in which dietary fat was reduced to 10%-12% of calories compared with 18%-25% of calories in the other studies. A statistically significant reduction in estradiol levels of -6.6% (95% CI = -10.3% to -2.7%) remained after exclusion of these two studies. Review of prospective analytic epidemiologic studies that allowed for dietary measurement error suggests that the possibility that reducing fat consumption below 20% of calories will reduce breast cancer risk cannot be excluded. IMPLICATIONS: Dietary fat reduction can result in a lowering of serum estradiol levels and such dietary modification may still offer an approach to breast cancer prevention. (+info)Postmenopause is a stage in a woman's life that follows 12 months after her last menstrual period (menopause) has occurred. During this stage, the ovaries no longer release eggs and produce lower levels of estrogen and progesterone hormones. The reduced levels of these hormones can lead to various physical changes and symptoms, such as hot flashes, vaginal dryness, and mood changes. Postmenopause is also associated with an increased risk of certain health conditions, including osteoporosis and heart disease. It's important for women in postmenopause to maintain a healthy lifestyle, including regular exercise, a balanced diet, and routine medical check-ups to monitor their overall health and manage any potential risks.
Perimenopause is a term used to describe the phase before menopause where the ovaries gradually begin to produce less estrogen. It's also sometimes referred to as the "menopausal transition."
This stage can last for several years, typically starting in a woman's mid-40s, but it can begin in some women as early as their mid-30s or as late as their early 50s. During this time, menstrual cycles may become longer or shorter, and periods may be lighter or heavier.
The most significant sign of perimenopause is the irregularity of periods. However, other symptoms such as hot flashes, sleep disturbances, mood changes, and vaginal dryness can also occur, similar to those experienced during menopause.
Perimenopause ends after a woman has gone 12 months without having a period, which marks the start of menopause.
Menopause is a natural biological process that typically occurs in women in their mid-40s to mid-50s. It marks the end of menstrual cycles and fertility, defined as the absence of menstruation for 12 consecutive months. This transition period can last several years and is often accompanied by various physical and emotional symptoms such as hot flashes, night sweats, mood changes, sleep disturbances, and vaginal dryness. The hormonal fluctuations during this time, particularly the decrease in estrogen levels, contribute to these symptoms. It's essential to monitor and manage these symptoms to maintain overall health and well-being during this phase of life.
A hot flash is a sudden, intense feeling of heat, particularly in the face, neck and chest regions, which is often accompanied by perspiration, reddening of the skin (flush or blush), and rapid heartbeat. It is a common symptom experienced by individuals, especially women during menopause or perimenopause, although it can also occur in other medical conditions or as a side effect of certain medications. The exact cause of hot flashes is not fully understood, but they are thought to be related to changes in hormone levels and the body's regulation of temperature.
Premenopause is not a formal medical term, but it's often informally used to refer to the time period in a woman's life leading up to menopause. During this stage, which can last for several years, hormonal changes begin to occur in preparation for menopause. The ovaries start to produce less estrogen and progesterone, which can lead to various symptoms such as irregular periods, hot flashes, mood swings, and sleep disturbances. However, it's important to note that not all women will experience these symptoms.
The official medical term for the stage when a woman's period becomes irregular and less frequent, but hasn't stopped completely, is perimenopause. This stage typically lasts from two to eight years and ends with menopause, which is defined as the point when a woman has not had a period for 12 consecutive months. After menopause, women enter postmenopause.
Estrogen Replacement Therapy (ERT) is a medical treatment in which estrogen hormones are administered to replace the estrogen that is naturally produced by the ovaries but declines, especially during menopause. This therapy is often used to help manage symptoms of menopause such as hot flashes, night sweats, and vaginal dryness. It can also help prevent bone loss in postmenopausal women. ERT typically involves the use of estrogen alone, but in some cases, a combination of estrogen and progestin may be prescribed for women with a uterus to reduce the risk of endometrial cancer. However, ERT is associated with certain risks, including an increased risk of breast cancer, blood clots, and stroke, so it's important for women to discuss the potential benefits and risks with their healthcare provider before starting this therapy.
Women's health is a branch of healthcare that focuses on the unique health needs, conditions, and concerns of women throughout their lifespan. It covers a broad range of topics including menstruation, fertility, pregnancy, menopause, breast health, sexual health, mental health, and chronic diseases that are more common in women such as osteoporosis and autoimmune disorders. Women's health also addresses issues related to gender-based violence, socioeconomic factors, and environmental impacts on women's health. It is aimed at promoting and maintaining the physical, emotional, and reproductive well-being of women, and preventing and treating diseases and conditions that disproportionately affect them.
Follicle-Stimulating Hormone (FSH) is a glycoprotein hormone secreted and released by the anterior pituitary gland. In females, it promotes the growth and development of ovarian follicles in the ovary, which ultimately leads to the maturation and release of an egg (ovulation). In males, FSH stimulates the testes to produce sperm. It works in conjunction with luteinizing hormone (LH) to regulate reproductive processes. The secretion of FSH is controlled by the hypothalamic-pituitary-gonadal axis and its release is influenced by the levels of gonadotropin-releasing hormone (GnRH), estrogen, inhibin, and androgens.
Longitudinal studies are a type of research design where data is collected from the same subjects repeatedly over a period of time, often years or even decades. These studies are used to establish patterns of changes and events over time, and can help researchers identify causal relationships between variables. They are particularly useful in fields such as epidemiology, psychology, and sociology, where the focus is on understanding developmental trends and the long-term effects of various factors on health and behavior.
In medical research, longitudinal studies can be used to track the progression of diseases over time, identify risk factors for certain conditions, and evaluate the effectiveness of treatments or interventions. For example, a longitudinal study might follow a group of individuals over several decades to assess their exposure to certain environmental factors and their subsequent development of chronic diseases such as cancer or heart disease. By comparing data collected at multiple time points, researchers can identify trends and correlations that may not be apparent in shorter-term studies.
Longitudinal studies have several advantages over other research designs, including their ability to establish temporal relationships between variables, track changes over time, and reduce the impact of confounding factors. However, they also have some limitations, such as the potential for attrition (loss of participants over time), which can introduce bias and affect the validity of the results. Additionally, longitudinal studies can be expensive and time-consuming to conduct, requiring significant resources and a long-term commitment from both researchers and study participants.
Aging is a complex, progressive and inevitable process of bodily changes over time, characterized by the accumulation of cellular damage and degenerative changes that eventually lead to increased vulnerability to disease and death. It involves various biological, genetic, environmental, and lifestyle factors that contribute to the decline in physical and mental functions. The medical field studies aging through the discipline of gerontology, which aims to understand the underlying mechanisms of aging and develop interventions to promote healthy aging and extend the human healthspan.
Medical Definition:
"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.
Postmenopausal confusion